Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. announced the successful completion of a fundraising initiative, generating approximately £11.0 million in gross proceeds. The funds will be used to support a Phase 3 clinical trial, commercial growth, production, and operations, extending the company’s cash runway through the first half of 2026. The fundraising saw significant participation from existing shareholders and directors, underscoring confidence in the company’s strategic direction.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, also known as photodisinfection. The company has a range of investigational products in development, leveraging its proprietary photodisinfection technology.
Average Trading Volume: 263,682
Technical Sentiment Signal: Buy
Current Market Cap: £73.3M
See more data about OBI stock on TipRanks’ Stock Analysis page.